Navigation Links
PTC Therapeutics Announces Pharmacokinetic and Safety Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy
Date:10/11/2007

ase 1 clinical trials, PTC124 was generally well tolerated, achieved target plasma concentrations that have been associated with activity in preclinical models and did not induce ribosomal read through of normal stop codons. PTC is currently conducting Phase 2 clinical trials of PTC124 in nonsense-mutation-mediated cystic fibrosis (CF) and Duchenne muscular dystrophy (DMD).

It is estimated that 10% of the cases of CF and 13% of the cases of DMD are due to nonsense mutations. PTC believes that PTC124 is potentially applicable to a broad range of other genetic disorders in which a nonsense mutation is the cause of the disease. The FDA has granted PTC124 Fast-Track designations and Orphan Drug designations for the treatment of CF and DMD due to nonsense mutations. PTC124 has also been granted orphan drug status for the treatment of CF and DMD by the European Commission. PTC124's development is supported by grants from the Muscular Dystrophy Association (MDA), Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), Parent Project Muscular Dystrophy (PPMD), FDA's Office of Orphan Products Development (OOPD) and by General Clinical Research Center grants from the National Center for Research Resources (NCRR).

About PTC Therapeutics, Inc.

PTC is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary, small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC's internally- discovered pipeline addresses multiple therapeutic areas, including genetic disorders, oncology and infectious diseases. In addition, PTC has developed proprietary technologies and extensive knowledge of post-transcriptional control processes that it applies in its drug discovery and development activities, including the Gene Expression Modulation by Small-m
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... -- CANTEL MEDICAL CORP. (NYSE: CMN ) announced today ... be presenting at the Bank of America Merrill Lynch 2015 ... Las Vegas, NV. The formal presentation is ... PM ET. In addition, management will be available for separate ... webcast will be available via the investor relations page of ...
(Date:5/1/2015)... Mass. , May 1, 2015  Portal Instruments, ... drug delivery systems, announced today that Robert Langer, ... , Ph.D., University of Auckland Distinguished Professor have joined ... thrilled to welcome two esteemed biotechnology leaders, Professor ... to our team," said Dr. Patrick Anquetil , ...
(Date:5/1/2015)... , May 1, 2015  Thoratec Corporation (NASDAQ: THOR ... save, support and restore failing hearts, announced today that ... role of President, International. This new ... operations outside of North America , including ... and Latin America , and reports directly ...
Breaking Medicine Technology:Portal Instruments Adds Two Esteemed Biotechnology Leaders to its Scientific Advisory Board 2Portal Instruments Adds Two Esteemed Biotechnology Leaders to its Scientific Advisory Board 3Portal Instruments Adds Two Esteemed Biotechnology Leaders to its Scientific Advisory Board 4Thoratec Announces Addition To Senior Management Team 2Thoratec Announces Addition To Senior Management Team 3
... Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, will ... at 8:30 AM ET, to discuss its financial results ... issue its quarterly financial results press release before the ... participate in the live conference call, please dial 800-510-9691 ...
... Hospira, Inc. (NYSE: HSP ), a leading ... results for the first quarter ended March 31, 2011. ... adjusted* diluted earnings per share were $0.93. (Adjusted* measures ... press release and the attached schedules.) "Hospira ...
Cached Medicine Technology:Insmed to Host 2011 First Quarter Earnings Conference Call 2Hospira Reports First-Quarter 2011 Results 2Hospira Reports First-Quarter 2011 Results 3Hospira Reports First-Quarter 2011 Results 4Hospira Reports First-Quarter 2011 Results 5Hospira Reports First-Quarter 2011 Results 6Hospira Reports First-Quarter 2011 Results 7Hospira Reports First-Quarter 2011 Results 8Hospira Reports First-Quarter 2011 Results 9Hospira Reports First-Quarter 2011 Results 10Hospira Reports First-Quarter 2011 Results 11Hospira Reports First-Quarter 2011 Results 12Hospira Reports First-Quarter 2011 Results 13
(Date:5/1/2015)... Pioneer Millworks, the largest reclaimed wood ... their reclaimed wood products at the 27th annual International ... in NYC this May. Their newest offerings, Vat 35, ... texture and color to North America's platform for global ... and color in the design world and we're excited ...
(Date:5/1/2015)... (PRWEB) May 01, 2015 Royal River ... Freeport, Maine, reports on a new study that found ... joint swelling and improved physical function as well as ... severe osteoarthritis of the knee. , The report is ... Insights for Well Being® ,” which Royal River Natural ...
(Date:5/1/2015)... Mesa, CA (PRWEB) May 01, 2015 ... at the Cerner Southeast Regional User Group (RUG) Conference ... The Cerner Southeast Regional User Group Conference provides a ... to vendors who support all aspects of electronic medical ... use of Cerner software applications. , In addition to ...
(Date:5/1/2015)... Bridge, NJ (PRWEB) May 01, 2015 ... their continued support of Hope For The Warriors® and ... totaling $20K to support Hope For The Warriors®, a ... restoring the family unit, and restoring hope for our ... beneficiary autograph signings, All American Ford collected and matched ...
(Date:5/1/2015)... 01, 2015 The fields of genetics ... the interplay of genes with one another and the ... be daunting. , LabRoots, the premier producer of interactive ... will soon host its annual conference spotlighting the recent ... Live Genetics and Genomics 2015 , a two-day event ...
Breaking Medicine News(10 mins):Health News:Intensely Textured Reclaimed Wood to be Unveiled at ICFF in NYC by Pioneer Millworks 2Health News:Intensely Textured Reclaimed Wood to be Unveiled at ICFF in NYC by Pioneer Millworks 3Health News:New Study Finds Nutrients Ease Arthritis Pain, Retailer Reports 2Health News:TROY Healthcare to Exhibit at the Cerner Southeast Regional User Group Conference 2Health News:TROY Healthcare to Exhibit at the Cerner Southeast Regional User Group Conference 3Health News:All American Ford Presents Donation to Nonprofit Hope For The Warriors 2Health News:Recent Advances in Genetics and Genomics: A BioConference Live 2015 Virtual Event 2Health News:Recent Advances in Genetics and Genomics: A BioConference Live 2015 Virtual Event 3
... have identified a key receptor that could be a potential ... distress syndrome (ARDS). //The condition is sudden in onset and ... similar to what triggers the sense of sight, smell and ... ARDS in which the body's own fluid gets trapped in ...
... ‘Inflatable-pants' heart failure therapy lack of conclusive evidence it ... to support a device that uses balloon-like pants as ... technique in question is called “External counterpulsation”(ECP), a noninvasive ... is most commonly used to relieve hard-to-treat chest pain ...
... by the Bihar government on Wednesday for neglecting their ... Minister of Bihar Mr. Nitish Kumar gave the nod ... was carried out with immediate effect. ,Last ... departmental proceedings against 16 doctors for neglecting duties. ...
... effect caused by the bird flu threat has resulted in ... the Indian capital. One can see that in Gazipur wholesale ... // ,Only those chickens that were certified by ... for Rs.20-25, whereas those that were uncertified was available for ...
... in two Australian children, according to reports published today ... known to lead to a host of problems including ... ,Professor Cres Eastman, one among Australia’s leading endocrinologists has ... call to the authorities who seem to be very ...
... announced the approval of a new antifungal drug, for ... new drug called Eraxis, // is indicated in the ... ,The improved performance of Eraxis compared to ... have supported the approval. The drug can also be ...
Cached Medicine News:Health News:'Inflatable-pants' heart failure therapy suffers due to lack of evidence. 2Health News:Delhi Sees Sharp Decline In Chicken Prices 2Health News:Delhi Sees Sharp Decline In Chicken Prices 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: